Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
Ventyx Biosciences (VTYX) Stock Price & Analysis
214 Followers
VTYX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.87 - $40.58
Previous Close$4.73
Volume511.07K
Average Volume (3M)3.87M
Market Cap
$333.46M
Enterprise Value$44.97M
Total Cash (Recent Filing)$300.82M
Total Debt (Recent Filing)$12.33M
Price to Earnings (P/E)-1.5
Beta0.50
Next Earnings
Aug 12, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.24
Shares Outstanding70,499,332
10 Day Avg. Volume641,030
30 Day Avg. Volume3,874,724
Standard Deviation0.52
R-Squared0.00233
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)1.44
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$11.57Price Target Upside144.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Ventyx Biosciences News
PremiumCompany Announcements
Ventyx Biosciences Names Matthew Moore New COO
PremiumCompany Announcements
Ventyx Biosciences CBO Christopher Krueger Steps DownBulls Say, Bears Say
Bulls Say
Drug Development ProgressVentyx Biosciences' significant progress in drug development is demonstrated by positive results from Phase 1 and Phase 2 trials.
Financial HealthVentyx has a strong cash position, maintaining sufficient funds to support its operations well into the future, ensuring ongoing research and development activities.
Potential Market ImpactPositive trial results from NodThera could serve as a benchmark, indicating potential for successful outcomes for Ventyx’s similar mechanism NLRP3 inhibitors in treating obesity.
Bears Say
Clinical Trial ResultsBMS announced that the primary endpoint of clinical remission at week 12 was not met with Zeposia in the Phase 3 YELLOWSTONE clinical trial for Crohn's disease.
Company FundingThe company has an annualized cash burn of $166.0 million, which poses a risk of depleting their financial resources.
Financial StrategyVentyx is seeking a partner or other source of non-dilutive financing to fund the Phase 3 program for its candidate VTX002.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $1.86 and its highest was $40.58 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Currently, no data Available
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is Aug 12, 2024 which is in 85 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on May 09, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.681 by $0.061.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Undervalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate is -$0.58.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 70,499,330 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.681. Following the earnings report the stock price went down -8.705%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Among the largest hedge funds holding Ventyx Biosciences’s share is Graham Capital Management, L.P.. It holds Ventyx Biosciences’s shares valued at 1M.
---
Ventyx Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.57 (144.61% Upside)
$11.57 (144.61% Upside)
Blogger Sentiment
Neutral
VTYX Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $48.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.39%
12-Months-Change
Fundamentals
Return on Equity
-56.76%
Trailing 12-Months
Asset Growth
-14.67%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
---
VTYX Earnings Call
Q1 2024
0:00 / 0:00
---
VTYX Stock 12 Month Forecast
Average Price Target
$11.57
▲(144.61% Upside)
Technical Analysis
Best Analysts Covering VTYX
1 Year
1 Year Success Rate
7/20 ratings generated profit
1 Year Average Return
-6.14%
reiterated a buy rating 9 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -6.14% per trade.
---